Grade Post Therapy Clin (yc)
Notes
**Note 1:** Leave Grade Post Therapy Clin (yc) blank when * No neoadjuvant therapy * Clinical or pathological case only * Neoadjuvant therapy completed, no microscopic exam is done prior to surgery/resection of primary tumor * There is only one grade available and it cannot be determined if it is clinical, pathological, post therapy clinical or post therapy pathological **Note 2:** Assign the highest grade from the microscopically sampled specimen of the primary site following neoadjuvant therapy or primary systemic/radiation therapy. **Note 3:** If there are multiple tumors with different grades abstracted as one primary, code the highest grade. **Note 4:** Codes 1-4 take priority over codes A-D. **Note 5:** Code 9 (unknown) when * Microscopic exam is done after neoadjuvant therapy and grade from the primary site is not documented * Microscopic exam is done after neoadjuvant therapy and there is no residual cancer * Grade checked “not applicable” on CAP Protocol (if available) and no other grade information is availableNAACCR Item
NAACCR #1068Metadata
SSDI| Code | Description |
|---|---|
| 1 | G1: Nucleoli absent or inconspicuous and basophilic at 400x magnification Stated as WHO/ISUP Grade 1 |
| 2 | G2: Nucleoli conspicuous and eosinophilic at 400x magnification, visible but not prominent at 100x magnification Stated as WHO/ISUP Grade 2 |
| 3 | G3: Nucleoli conspicuous and eosinophilic at 100x magnification Stated as WHO/ISUP Grade 3 |
| 4 | G4: Marked nuclear pleomorphism and/or multinucleate giant cells and/or rhabdoid and/or sarcomatoid differentiation Stated as WHO/ISUP Grade 4 |
| A | Well differentiated |
| B | Moderately differentiated |
| C | Poorly differentiated |
| D | Undifferentiated, anaplastic |
| 9 | Grade cannot be assessed (GX); Unknown Only Fuhrman grade documented |
| <BLANK> | See Note 1 |